• 00Days
  • 00Hrs
  • 00Mins
  • 00Secs

Prof. Dr. Yi Liu

West China Hospital Of Sichuan University, China

Curriculum Vitae (Yi Liu, MD, PhD)

Present Title and Affiliation:
Professor of Medicine,Director of Dept of Rheumatology and Immunology,West China Hospital of Sichuan University
Office Address:
Dept of Rheumatology and Immunology, West China Hospital of Sichuan University 37 Guoxue Lane, Chengdu, Sichuan Province
Email : yi2006liu@163.com
Tel :86-18980602061

09/1979 – 08/1984 MD, Qingdao Medical college of Qingdao University, Qingdao, Shandong Province
08/1988 – 07/1993 PhD, Academy of PLA Medical Sciences/PLA General Hospital, Beijing, China
03/1998 – 09/2001 PostDoc Researcher, Division of Rheumatology, Turku Department,Finland National Health Institute, Turku, Finland, Mentor: Prof. Kaisa Granfors
09/2001 – 09/2002 PostDoc Scientist, Health Science Center, Tennessee University, Mentor: Tony Marion
09/2002 – 04/2006 Postdoc Researcher, Department of Rheumatology, Marry kirkland Lupus Research Center, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA,

Mentor: Luminita Pricop

Professional Societies:
Since 2020, Chairman, Rheumatology Association of Sichuan Province
Since 2015, Vice Chairman, Chinese Rheumatology physician’s Association
2016-2019, Vice Chairman, Chinese Rheumatology Association
Since 2017, Vice Chairman, Chinese Rehabilitation Association, (Bone, Joint and Rheumatology Association)

Journal Reviewer:
Chinese Journal of Internal Medicine
Chinese Journal of Rheumatology
Medical Journal of West China

Awards and Grands:
1975, First Class, Award of PLA Science and Technology (Study of mechanism of Spondyloarthropathies);
2008, First Class, Awards of Sichuan Science and Technology (Study of mechanism of Spondyloarthropathies);
2009, National Science and Technology Grand, (Mechanisms of STIM1 modulated dendritic cells maturation)
2010, Sichuan International Exchange Fund, (Establishing the VDR therapeutic system for Spondyloarthropathies);
2019, First Class, Sichuan Medical Science and Technology Award(Clinical intervention and immune-inflammation regulation strategies for rheumatic diseases)
Original Papers:
1. Pan S Y, Cheng R J, Xia Z J, et al. Risk of dementia in gout and hyperuricaemia: a meta-analysis of cohort studies[J]. BMJ open, 2021, 11(6): e041680.(IF:2.692)
2. Xia Z J, He L, Pan S Y, et al. Disease Severity Determines Timing of Initiating Continuous Renal Replacement Therapies: A Systematic Review and Meta-Analysis[J]. Frontiers in Medicine, 2021, 8.(IF:5.0929)
3. Tang Z, Wang X, Xia Z, et al. Case Report: Multicentric Reticulohistiocytosis Associated With Posterior Mediastinal Adenosquamous Carcinoma, Antinuclear Antibody Positivity and Lupus Anticoagulant Positivity[J]. Frontiers in immunology, 2021, 12.(IF:7.5607)
4. Zhang H, Yin Y, Wang H, et al. Identification of Self-Management Behavior Clusters Among People Living with HIV in China: A Latent Class Profile Analysis[J]. Patient preference and adherence, 2021, 15: 1427.(IF:2.711)
5. Huang T, Li Y, Luo Y, et al. Research progress on the pathogenesis and quality of life of patients with primary Sjögren’s syndrome complicated by depression[J]. Clinical and Experimental Rheumatology, 2021.(IF:4.473)
6. Wu Q, Liu Y, Xie Y, et al. Identification of potential ceRNA network and patterns of immune cell infiltration in systemic sclerosis-associated interstitial lung disease[J]. Frontiers in Cell and Developmental Biology, 2021, 9.(IF:6.684)
7. Pan S, Xia Z, Liu Y, et al. Effect of benzbromarone combined with sodium bicarbonate in the treatment of gouty arthritis[J]. Minerva Medica, 2020.(IF:3.031)
8. Chen B, Gu H Q, Liu Y, et al. A model to predict the risk of mortality in severely ill COVID-19 patients[J]. Computational and Structural Biotechnology Journal, 2021, 19: 1694-1700.(IF:6.0176)
9. Li C Y, Ou R W, Chen Y P, et al. Genetic Analysis of ZNF Protein Family Members for Early-Onset Parkinson’s Disease in Chinese Population[J]. Molecular Neurobiology, 2021: 1-8.(IF:4.5007)
10. Wang Y, Ding L, Chen J, et al. Risk Factors for Progression from Subclinical to Clinical Phase of Psoriatic Arthritis: A Case–Control Study[J]. Rheumatology and Therapy, 2021, 8(1): 585-597. (IF:3.614)
11. Yang Y, Zhu S, Li Y, et al. Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis[J]. Experimental and therapeutic medicine, 2020, 20(6): 1-1.(IF:1.785)
12. Yang P, Pi X, Marion T N, et al. Gout inheritance in an extended Chinese family analyzed by whole-exome sequencing: A case-report[J]. Medicine, 2020, 99(25).(IF:1.552)
13. Chen A, Cui B, Li Y, et al. Kimura’s disease and ankylosing spondylitis: A case report[J]. Medicine, 2020, 99(34).(IF:1.552)
14. Liu Z Z, Wu Y, Wei S, et al. Self-balance of intestinal flora in spouses of patients with rheumatoid arthritis[J]. Frontiers in Medicine, 2020, 7: 538.(IF:3.9)
15. Tong Y, Marion T, Schett G, et al. Microbiota and metabolites in rheumatic diseases[J]. Autoimmunity Reviews, 2020: 102530.(IF:7.767)
16. Xie Y, Xiong A, Marion T, et al. Lung nodules and IgG4 related disease: a single-center based experience[J]. BMC Pulmonary Medicine, 2020, 20(1).(IF:2.813)
17. Lu C, Li S, Liu Y. Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19[J]. Annals of the Rheumatic Diseases, 2020, 79(6): 737-739.(IF:14.299)
18. Ma L, Liang Y, Yu S, et al. Assessment of the practicability of implementing the EULAR recommendations for the role of nurses in the management of chronic inflammatory arthritis in China[J]. European Journal of Inflammation, 2020, 18: 2058739220935225.(IF:0.267)
19. Lu C, Wallace B I, Waljee A K, et al. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis[C]//Seminars in arthritis and rheumatism. WB Saunders, 2019, 49(3): 381-388.(IF:5.072)
20. Cheng R J, Xiong A J, Li Y H, et al. Mesenchymal stem cells: allogeneic MSC may be immunosuppressive but autologous MSC are dysfunctional in lupus patients[J]. Frontiers in Cell and Developmental Biology, 2019, 7: 285.(IF:5.206)
21. Yang P, Li Y, Xie Y, et al. Different faces for different places: heterogeneity of neutrophil phenotype and function[J]. Journal of Immunology Research, 2019, 2019.(IF:3.298)
22. Guo J, Yang Z C, Liu Y. Attenuating pulmonary hypertension by protecting the integrity of glycocalyx in rats model of pulmonary artery hypertension[J]. Inflammation, 2019, 42(6): 1951-1956.(IF:2.939)
23. Zou Q, Zhao Y, Wang Y, et al. Associations between IL-23R gene polymorphisms and the susceptibility of rheumatoid arthritis: a meta-analysis[J]. Artificial cells, nanomedicine, and biotechnology, 2019, 47(1): 951-956.(IF:3.026)
24. Lan Y Y, Wang Y Q, Liu Y. CCR5 silencing reduces inflammatory response, inhibits viability, and promotes apoptosis of synovial cells in rat models of rheumatoid arthritis through the MAPK signaling pathway[J]. Journal of cellular physiology, 2019, 234(10): 18748-18762.(IF:4.522)
25. Zou Q, Zhao Y, Wang Y, et al. Correlation of Polymorphisms of Natural Resistance-Associated Macrophage Protein 1 (NRAMP1) Gene and Smoking with the Risk of Rheumatoid Arthritis in Chinese Han People[J]. Medical science monitor: international medical journal of experimental and clinical research, 2019, 25: 5321.(IF:1.98)
26. Li Y, Wang Z, Zhao Y, et al. Successful mesenchymal stem cell treatment of leg ulcers complicated by Behcet disease: A case report and literature review[J]. Medicine, 2018, 97(16).(IF:2.028)
27. Bai Y, Tong Y, Liu Y, et al. Self‐dsDNA in the pathogenesis of systemic lupus erythematosus[J]. Clinical & Experimental Immunology, 2018, 191(1): 1-10.(IF:3.41)
28. Lu C, Liu Y. Comment on: Efficacy and safety of biologics targeting interleukin-6,-12/23 and-17 pathways for peripheral psoriatic arthritis: a network meta-analysis[J]. Rheumatology, 2018, 57(11): 2061-2062.(IF:5.149)

Translate »